Conference Reports for NATAP

Back

61th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010     Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment - press release from Vertex - (08/11/10)   BMS-824393 Is a Potent Hepatitis C Virus NS5A Inhibitor With Substantial Antiviral Activity When Given as Monotherapy in Subjects With Chronic G1 HCV Infection - (06/01/11)   A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naïve Genotype 1 HCV-Infected Subjects - (12/13/10)   Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor - (12/13/10)   Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C - (12/13/10)   Steatosis, Obesity, Peg-IFN Dose Reduction & Menopause are Associated with Relapse in Chronic Hepatitis C Patients Treated with Pegylated Interferon Plus Ribavirin - (12/13/10)   IL-28B Genotype is a Major Determinant of the Induction of a Virological Response by High-Dose Peginterferon and Ribavirin in Null-responders to SOC Therapy: Pegasys double-dose significantly increased early virologic response - (12/13/10)   Viread(R) for Hepatitis B Maintains Antiviral Suppression with No Development of Resistance Through Four Years of Treatment - (11/29/10)   New HCV Drugs at AASLD - (11/29/10)   Assessment of Hepatitis C Virus Attitudes Towards Treatment Among Methadone Maintenance Treatment Program Staff - (11/29/10)   Ultra-Deep Sequencing of the NS3 and NS5B Regions Detects Pre-Existing Resistant Variants to Direct Acting Antivirals (DAA) in HCV Genotype 1 Treatment-Naïve Infected Patients - (11/29/10)   Low rate of viral load rebound observed among treatment-naive genotype 1 patients with chronic hepatitis C treated with danoprevir (RG7227) plus Peg-IFN α-2a (40KD) (PEG ASYS) plus ribavirin: interim analysis - (11/21/10)   Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5 days' monotherapy - (11/21/10)   No evidence of drug resistance or baseline S282T resistance mutation among GT 1 and GT 4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study - (11/21/10)   Analysis of Resistance-Associated Mutations in Patients treated with narlaprevir and subsequently standard of care - (11/21/10)   Chronic Hepatitis C (HCV) Infections and the Risk of Depression and Other Adverse Events - (11/21/10)   In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters - (11/21/10)   Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ATLAS study - (11/21/10)   Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest [FT]/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program - (11/21/10)   No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based Regimen in HCV Genotype 1 Treatment-naïve Patients: Subanalysis of C208 Study - (11/21/10)   Differential association of a chromosome 19 single nucleotide polymorphism (SNP: rs12979860) to outcome (early virologic response/sustained virologic response [EVR /SVR]) in naive vs. retreated HCV patients treated with IFN-based therapies - (11/21/10)   Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians With HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027 - (11/21/10)   Long-term Entecavir Treatment for Up to 5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results From ETV-022 and -901 - (11/21/10)   Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/21/10)   Safety Findings From S-Collate, A Large, Multinational, Non-Interventional Cohort Study Of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40kd] - (11/21/10)   Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience - (11/21/10)   Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40KD] in genotype D patients with HBeAg-negative chronic hepatitis B - (11/21/10)   Changes In HBsAg Levels Among Patients With Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40kd] Enrolled In The S-Collate Cohort Study - (11/21/10)   Changes In HBeAg Levels Among Patients With HBeAg-Positive Chronic Hepatitis B Treated With Peginterferon Alfa-2a [40KD] Enrolled In The S-Collate Cohort Study - (11/21/10)   Telaprevir Resistance Disappears in 89% of Patients: Long-Term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis from the EXTEND Study - (11/15/10)   Effectiveness and safety of Tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B - (11/15/10)   Coadministration of BMS-790052 and BMS-650032 Does Not Result in a Clinically Meaningful Pharmacokinetic Interaction in Healthy Subjects - (11/15/10)   Gilead's New HCV Drugs Studies & HBV at AASLD - (11/15/10)   36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: Final results of a randomized multicenter study - (11/14/10)   Genotype 1b vs 1a and Peg/Rbv Lead-In - (11/12/10)   The Effect of Hepatitis C Treatment Response on Medical Costs: A 5-Year Longitudinal Analysis in a Managed Care Setting - (11/12/10)   Virological response and safety of 4 weeks' treatment with the protease inhibitor BI 201335combined with 48 weeks of peginterferon alfa 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon/ribavirin - (11/12/10)   BMS-790052, a First-in-Class Potent Hepatitis C Virus NS5A Inhibitor, Demonstrates Multiple-Dose Proof-of-Concept in Subjects With Chronic GT1 HCV Infection (potent, mean maximal 5.7 log reduction) - (11/10/10)   New HCV Drugs at AASLD, easy to understand report: (see links below to reports from AASLD) - (11/10/10)   No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus - (11/08/10)   Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 µg: NEPTUNE study - (11/08/10)   HCV New Drugs - (11/08/10)   Pegylated Interferon Lambda (pegIFNλ) Phase 2 Dose-Ranging, Active-Controlled Study in Combination With Ribavirin (RBV) for Treatment-Naive HCV Patients (Genotypes 1, 2, 3, or 4): Safety, Viral Response, and Impact of IL28B Host Genotype Through Week 12 - (11/08/10)   Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects - (11/08/10)   Rapid Progression to Decompensated Cirrhosis and Death in HIV-infected Men with Newly-acquired HCV Infection - (11/08/10)   A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6 - (11/08/10)   High Rapid Virologic Response (RVR) with PSI-7977 Daily Dosing plus PEG-IFN/RBV in a 28-day Phase 2a Trial - (11/08/10)   IL28B SNP Geographical Distribution and Antiviral Responses in a 28-day Phase 2a Trial of PSI-7977 Daily Dosing plus PEG-IFN/RBV - (11/08/10)   Clinical Synergy of an Anti-HCV Nucleotide Analog with SOC: Viral Kinetics of PSI-7977 with SOC - (11/08/10)   Pharmacokinetics, Safety, and Tolerability of PSI-352938, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Subjects - (11/08/10)   Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study - (11/07/10)   Three-Day, Dose-Ranging Study Of The HCV NS3 Protease Inhibitor GS-9451 - (11/07/10)   Antiviral Response and Resistance Analysis of Treatment-Naïve HCV Infected Subjects Receiving Single and Multiple Doses of GS-9190 - (11/07/10)   Safety, Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the HCV NS3 Protease Inhibitor GS-9256 - (11/07/10)   5 New Potent HCV Protease inhibitors - (11/05/10)   New HCV Drugs: R7128 nucleoside, PSI7977 nucleotide, PSI938 nucleotide, ANA598 nnrti (rash), danoprevir protease, IMO-2125, a TLR agonist - (11/05/10)   IMO-2125, a TLR9 Agonist, Induces Immune ResponsesWhich Correlate With Reductions In Viral Load In Null Responder HCV Patients - (11/05/10)   AASLD President's Choice Lecture: The National Strategy for the Control of Viral Hepatitis and Liver by Dr Howard Koh, HHS - (11/05/10)   Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1) - (11/05/10)   Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE - (11/04/10)   Dual, Triple, and Quadruple Combination Treatment with a Protease Inhibitor (GS-9256) and a Polymerase Inhibitor (GS-9190) alone and in Combination with Ribavirin (RBV) or PegIFN/RBV for up to 28 days in Treatment Naïve, Genotype 1 HCV Subjects - (11/04/10)   Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients - (11/04/10)   Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients with advanced chronic hepatitis C: extended follow - up results from the HALT - C Trial - (11/04/10)   Effects of Ribavirin Monotherapy on ALT, HCV Viral Levels, Serum Cytokines, and Hepatic Interferon - Stimulated Gene Expression in Chronic Hepatitis C - (11/04/10)   Sustained Virological Response of Antiviral Therapy and Clinical Outcomes in Elderly Patients with Compensated HCV - related Cirrhosis - (11/04/10)   Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial - (11/04/10)   Safety and Pharmacokinetics of PPI-461, a Potent New HCV NS5A Inhibitor with Pan-Genotype Activity - (11/04/10)   Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)   Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)   Coffee is associated with virologic response in chronic Hepatitis C: Findings from the Hepatitis C Long - Term Treatment against Cirrhosis Trial (HALT - C) . - (11/04/10)   Clinical, Virological, Biochemical Outcomes After 20 Years of Sustained Virological Response (SVR) in Chronic Hepatitis C: The NIH Experience. - (11/04/10)   Sustained Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-7009), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/04/10)   Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Naïve patients: Final results of Phase 3 ADVANCE Study - (11/04/10)   Phase 3 - Response Guided Therapy (RGT) - Boceprevir Combined with peginterferon alfa-2b plus ribavirin for treatment-naïve patients with HCV genotype 1 (SPRINT-2 Final Results) - (11/04/10)   Telaprevir Phase 3 ILLUMINATE Study - Final Results Reported at AASLD Nov 2 2010 - (11/04/10)   High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study - (11/04/10)   Response-Guided Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patientswith Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2 - (11/04/10)   Merck's Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure And Treatment-Naïve Adult Patients With Chronic Hepatitis C Genotype 1 Compared To Control - merck press release - (11/03/10)   Combination Therapy With BMS-790052 and BMS-650032 Alone or With Pegylated Interferon and Ribavirin (pegIFN/RBV) Results in Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (11/03/10)   Medivir Notes that Partner Tibotec Announced Week 24 Interim Results from Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD - (11/03/10)   Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C at AASLD - (11/03/10)   Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Naïve patients: Final results of Phase 3 ADVANCE Study - (11/02/10)   HCV RESPOND-2 Final Results: High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin - (11/02/10)   Efficacy and Safety of TMC435 in Combination With Peginterferon alfa-2a and Ribavirin in Treatment-naïve Genotype-1 HCV Patients: 24-Week Interim Results from the PILLAR Study - (11/02/10)   4-Week Virologic Response and Safety of ABT-450 Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day Monotherapy Then in Combination with Pegylated Interferon Alpha-2a and Ribavirin (SOC) in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects - (11/02/10)   HCV Late Breaker Posters this Morning at AASLD.....ABT450, BMS790052 NS5A+proteaseBMS650032, BI 201335+HCV polymerase inhibitor BI 207127+ribavirin - (11/02/10)   Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon - (11/01/10)   Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD - (11/01/10)   Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study - (11/01/10)   Merck Announces Pivotal Phase III Data for Boceprevir will be Presented at the American Association for the Study of Liver Diseases 2010 Annual Meeting - (11/01/10)   Telaprevir+pEg/RBV Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease - 'up to 88% in African-Americans' Vertex press release - (11/01/10)   Vertex's telaprevir and Merck's boceprevir: Compliance issues due to toxicity raise resistance concerns, physicians say - (11/01/10)   Bristol-Myers, Gilead and other companies Seek AIDS Cocktail Success in Hepatitis C: '2 oral HCV drugs in combination' - (11/01/10)   Black patients (& new HCV therapy) fare well on Vertex hepatitis C drug - (11/01/10)   Biolex Announces Locteron SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial - (10/28/10)   Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease - pdf attached - (10/28/10)   Pharmasset Announces Results of a 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection - (10/28/10)   Pharmasset Reports Positive Preliminary Antiviral Data with PSI-938 for the Treatment of Hepatitis C - (10/28/10)   Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C - (10/28/10)   Presidio Pharmaceuticals, Inc. to Present First Clinical Data for PPI-461, a New HCV NS5A inhibitor, at the American Association for the Study of Liver Diseases (AASLD) Meeting, Supporting Initiation of a Trial in Hepatitis C Patients - (10/28/10)